Arctic Bioscience (Buy, TP: NOK60.00) - Change at the helm
On 14 January, Arctic Bioscience announced there would be a change of CEO during Q1. We see no drama – while the current CEO has been instrumental in taking the company to the current point, a new leg of the journey will commence in 2022e as the large phase II trial in psoriasis is set to be initiated. We reiterate our BUY and NOK60 target price.
DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.